PharmaCyte Biotech (NASDAQ:PMCB) Issues Earnings Results

PharmaCyte Biotech (NASDAQ:PMCB) issued its quarterly earnings data on Monday. The company reported ($0.10) EPS for the quarter, Zacks reports.

PharmaCyte Biotech Price Performance

Shares of PharmaCyte Biotech stock remained flat at $1.58 during trading hours on Monday. The stock had a trading volume of 1,528 shares, compared to its average volume of 24,252. The stock has a market capitalization of $10.85 million, a PE ratio of 2.98 and a beta of -0.25. PharmaCyte Biotech has a 1 year low of $1.39 and a 1 year high of $2.58. The stock’s 50-day moving average is $1.65 and its two-hundred day moving average is $1.70.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.